Response to Lamotte et Al. "A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients.".
D003362:Cost-Benefit Analysis; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000191:economics; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D007004:Hypoglycemic Agents / Q000191:economics / Q000627:therapeutic use*; D007783:Lactones / Q000191:economics / Q000627:therapeutic use*; D009765:Obesity; D000077403:Orlistat
D007004:Hypoglycemic Agents; D007783:Lactones; D000077403:Orlistat